By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Korean molecular diagnostics firm Seegene today said it has raised $16.6 million in its initial public offering.

The company said it had sold 636,500 shares of its stock on the KOSDAQ (Korea Securities Dealers Automated Quotations) at KRW30,500 ($26.16) per share, and now has a market capitalization of $167 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.